Methylcobalamin Injection
Function and Efficacy
1 Pharmacological effects According to literature reports: 1) It has good transport into intracellular organelles in nerve cells and promotes the synthesis of nucleic acids and proteins. Compared with cyanocobalamin, it has good transport into intracellular organelles in nerve cells (rat). It plays a coenzyme role in the synthesis of methionine from homocysteine. In experiments on cells of brain origin and spinal cord nerve cells, it is particularly involved in the process of synthesizing thymine from deoxynucleotides and promotes the synthesis of nucleic acids and proteins (rat). 2) Promotes intra-axonal transport and axonal regeneration. In sciatic nerve cells of rats with diabetes induced by streptozotocin, it can normalize the transport of axonal structural proteins. It has no effect on adriamycin, acrylamide, and vincristine.
Ingredients
The main ingredient of this product is methylcobalamin, and its chemical name is: Coα-[α-(5,6-dimethylbenzimidazolyl)]-Coβ-methylcobaltamide.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| MecobalaminIngredients |
According to literature reports: 1) It has good transport to organelles in nerve cells, promotes the synthesis of nucleic acids and proteins, and is particularly involved in the synthesis of thymine from deoxynucleotides compared to cyanocobalamin; 2) It promotes intra-axonal transport and axonal regeneration, and can normalize the transport of axonal structural proteins in sciatic nerve cells of diabetic rats given streptozotocin. It has an ameliorative effect on neurotoxicity caused by doxorubicin, acrylamide, and vincristine (in mice). More |
13422-55-4 | 29 |
Appearance
This product is a red clear liquid.
Indication
1. Used for peripheral neuropathy. 2. Treatment of megaloblastic anemia caused by vitamin B12 deficiency.
Usage and Dosage
1. For adults with peripheral neuropathy, take 0.5 mg once a day, 3 times a week, intramuscularly or intravenously. The dosage can be increased or decreased according to age and symptoms. 2. For adults with megaloblastic anemia, take 0.5 mg once a day, 3 times a week, intramuscularly or intravenously. After about two months of administration, 0.7 mg can be given every 1 to 3 months as a maintenance treatment.
Adverse Reactions
1 Serious adverse reactions (frequency unknown) Allergic reactions: May cause allergic reactions such as decreased blood pressure and difficulty breathing. Patients should be closely observed. If such reactions occur, the medication should be discontinued immediately and appropriate measures should be taken. 2 Other adverse reactions (1) Allergic reactions: Rash occurs ((2) Others: Headache, fever (<0.1%): Sweating, pain at the intramuscular injection site, nodules (frequency unknown). If these adverse reactions occur, the medication should be discontinued.
Precautions
It is contraindicated for those who are allergic to this product or its ingredients.
Special Population Medication
Precautions for children: Not yet clear. Precautions for pregnancy and lactation: The safety of using this drug in pregnant and lactating women is not yet clear. Precautions for the elderly: Not yet clear.
Drug Interactions
Not yet clear.
Storage
Keep in a dark and airtight place. +24 months.
Packaging Specification
1ml:0.5mg
Validity Period
24 months.
Manufacturer
Harbin Medisan Pharmaceutical Co., Ltd.
-
Founded in:
1996-06-21 -
Address:
Beijing Road, Limin Development Zone, Harbin -
Tax NO.:
91230100607168790X -
Registered Funds:
316.35755 million yuan -
Website:
-
Email: